Latest TCG Crossover Management, LLC Stock Portfolio
TCG Crossover Management, LLC Performance:
2024 Q3: 8.19%YTD: 3.35%2023: 6.57%
Performance for 2024 Q3 is 8.19%, and YTD is 3.35%, and 2023 is 6.57%.
About TCG Crossover Management, LLC and 13F Hedge Fund Stock Holdings
In it's latest 13F Holdings report, TCG Crossover Management, LLC reported an equity portfolio of $1.2 Billions as of 30 Sep, 2024.
The top stock holdings of TCG Crossover Management, LLC are , DYN, COGT. The fund has invested 11.7% of it's portfolio in CG ONCOLOGY, INC. and 8.1% of portfolio in DYNE THERAPEUTICS, INC.
The fund managers got completely rid off MADRIGAL PHARMACEUTICALS INC (MDGL), SOLENO THERAPEUTIVS, INC. (SLNO) and ADVERUM BIOTECHNOLOGIES, INC. (ADVM) stocks. They significantly reduced their stock positions in TARSUS PHARMACEUTICALS, INC. (TARS), MINERALYS THERAPEUTICS, INC. and EDGEWISE THERAPEUTICS, INC. (EWTX). TCG Crossover Management, LLC opened new stock positions in XENCOR INC (XNCR), THIRD HARMONIC BIO INC (THRD) and SOLENO THERAPEUTIVS, INC. (SLNO). The fund showed a lot of confidence in some stocks as they added substantially to STRUCTURE THERAPEUTICS INC and KODIAK SCIENCES INC (KOD).
The top stock holdings of TCG Crossover Management, LLC are , DYN, COGT. The fund has invested 11.7% of it's portfolio in CG ONCOLOGY, INC. and 8.1% of portfolio in DYNE THERAPEUTICS, INC.
The fund managers got completely rid off MADRIGAL PHARMACEUTICALS INC (MDGL), SOLENO THERAPEUTIVS, INC. (SLNO) and ADVERUM BIOTECHNOLOGIES, INC. (ADVM) stocks. They significantly reduced their stock positions in TARSUS PHARMACEUTICALS, INC. (TARS), MINERALYS THERAPEUTICS, INC. and EDGEWISE THERAPEUTICS, INC. (EWTX). TCG Crossover Management, LLC opened new stock positions in XENCOR INC (XNCR), THIRD HARMONIC BIO INC (THRD) and SOLENO THERAPEUTIVS, INC. (SLNO). The fund showed a lot of confidence in some stocks as they added substantially to STRUCTURE THERAPEUTICS INC and KODIAK SCIENCES INC (KOD).
TCG Crossover Management, LLC Annual Return Estimates Vs S&P 500
Our best estimate is that TCG Crossover Management, LLC made a return of 8.19% in the last quarter. In trailing 12 months, it's portfolio return was 14.76%.
New Buys
| Ticker | $ Bought |
|---|---|
| xencor inc | 48,809,700 |
| third harmonic bio inc | 32,723,200 |
| soleno therapeutivs, inc. | 27,769,500 |
| fulcrum therapeutics inc | 18,742,500 |
| mbx biosciences inc | 16,887,000 |
| amylyx pharmaceuticals inc | 15,046,000 |
| adverum biotechnologies, inc. | 14,098,500 |
| vistagen therapeutics inc | 8,056,500 |
New stocks bought by TCG Crossover Management, LLC
Additions
| Ticker | % Inc. |
|---|---|
| structure therapeutics inc | 53.05 |
| kodiak sciences inc | 12.02 |
Additions to existing portfolio by TCG Crossover Management, LLC
Reductions
| Ticker | % Reduced |
|---|---|
| tarsus pharmaceuticals, inc. | -58.33 |
| mineralys therapeutics, inc. | -22.45 |
| silence therapeutics plc | -7.94 |
| edgewise therapeutics, inc. | -7.03 |
TCG Crossover Management, LLC reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| vistagen therapeutics inc | -9,314,500 |
| adverum biotechnologies, inc. | -13,777,200 |
| c4 therapeutics, inc. | -5,897,770 |
| soleno therapeutivs, inc. | -22,440,000 |
| madrigal pharmaceuticals inc | -41,823,100 |
TCG Crossover Management, LLC got rid off the above stocks
Sector Distribution
TCG Crossover Management, LLC has about 63.8% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 63.8 |
| Others | 36.2 |
Market Cap. Distribution
TCG Crossover Management, LLC has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| SMALL-CAP | 51.7 |
| UNALLOCATED | 36.2 |
| MID-CAP | 8.1 |
| MICRO-CAP | 3.3 |
Stocks belong to which Index?
About 51.8% of the stocks held by TCG Crossover Management, LLC either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| RUSSELL 2000 | 51.8 |
| Others | 48.2 |
TCG Crossover Management, LLC Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of TCG Crossover Management, LLC
TCG Crossover Management, LLC has 36 stocks in it's portfolio. About 58.4% of the portfolio is in top 10 stocks. FULC proved to be the most loss making stock for the portfolio. CNTA was the most profitable stock for TCG Crossover Management, LLC last quarter.
Last Reported on: 14 Nov, 2024| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ADVM | adverum biotechnologies, inc. | 1.19 | 2,008,340 | 14,098,500 | new | |||
| ADVM | adverum biotechnologies, inc. | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| AMLX | amylyx pharmaceuticals inc | 1.27 | 4,643,810 | 15,046,000 | new | |||
| ANTX | an2 therapeutics, inc. | 0.14 | 1,555,120 | 1,663,980 | unchanged | 0.00 | ||
| ATXS | astria therapeutics, inc. | 2.58 | 2,761,860 | 30,408,100 | unchanged | 0.00 | ||
| AVTE | aerovate therapeutics inc | 0.40 | 2,240,810 | 4,683,290 | unchanged | 0.00 | ||
| AVTX | avalo therapeutics inc | 0.39 | 483,000 | 4,588,500 | new | |||
| CABA | cabaletta bio, inc | 0.04 | 86,795 | 409,672 | unchanged | 0.00 | ||
| CCCC | c4 therapeutics, inc. | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| CMPS | compass pathways plc | 2.06 | 3,858,000 | 24,305,400 | unchanged | 0.00 | ||
| CNTA | centessa pharmaceuticals plc | 3.92 | 2,890,820 | 46,224,100 | unchanged | 0.00 | ||
| COGT | cogent biosciences inc | 6.37 | 6,964,380 | 75,215,200 | unchanged | 0.00 | ||
| DYN | dyne therapeutics, inc | 8.06 | 2,650,150 | 95,193,400 | unchanged | 0.00 | ||
| EWTX | edgewise therapeutics, inc. | 4.78 | 2,112,980 | 56,395,500 | reduced | -7.03 | ||
| EYPT | eyepoint pharmaceuticals, inc. | 0.62 | 922,335 | 7,369,460 | unchanged | 0.00 | ||
| FULC | fulcrum therapeutics inc | 1.59 | 5,250,000 | 18,742,500 | new | |||
| KOD | kodiak sciences inc | 0.22 | 1,008,160 | 2,631,290 | added | 12.02 | ||
| KROS | keros therapeutics, inc. | 4.33 | 879,344 | 51,063,500 | unchanged | 0.00 | ||
| KURA | kura oncology inc | 2.36 | 1,423,640 | 27,818,000 | unchanged | 0.00 | ||
| MDGL | madrigal pharmaceuticals inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||